Ipca Laboratories Limited
IPCALAB
Rang in Aktien
#3404
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures... Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.
Aktienkurs
$20.02
Zuletzt synchronisiert: 2026-10-19
Marktkapitalisierung
$5.08B
Veränderung (1 Tag)
-1.65%
Veränderung (1 Jahr)
38.46%
Land
IN
Handel Ipca Laboratories Limited (IPCALAB)
Kategorie
Healthcare
Gewinn für Ipca Laboratories Limited (IPCALAB)
Gewinn im Jun 2026 TTM: $200.02M
Laut den aktuellen Finanzberichten von Ipca Laboratories Limited betragen die aktuellen Gewinne des Unternehmens $200.02M. Im Jahr 2024 erzielte das Unternehmen einen Gewinn von $100.31M, eine Steigerung gegenüber dem Gewinn im Jahr 2023, der $89.11M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Ipca Laboratories Limited von 2005 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $200.02M | 51.54% |
| 2025 | $131.99M | 31.59% |
| 2024 | $100.31M | 12.56% |
| 2023 | $89.11M | -39.31% |
| 2022 | $146.83M | -22.19% |
| 2021 | $188.69M | 92.38% |
| 2020 | $98.08M | 24.63% |
| 2019 | $78.69M | 76.36% |
| 2018 | $44.62M | 10.42% |
| 2017 | $40.41M | 135.71% |
| 2016 | $17.14M | -69.96% |
| 2015 | $57.08M | -45.77% |
| 2014 | $105.26M | 26.12% |
| 2013 | $83.46M | 16.17% |
| 2012 | $71.85M | -6.02% |
| 2011 | $76.45M | 28.95% |
| 2010 | $59.28M | 154.37% |
| 2009 | $23.31M | -46.79% |
| 2008 | $43.80M | 23.03% |
| 2007 | $35.60M | 112.82% |
| 2006 | $16.73M | -22.39% |
| 2005 | $21.55M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 782.18% |
IN
|
